Care Patterns and Overall Survival in Patients with Early-Onset Metastatic Colorectal Cancer

Katie Kanter, Madeleine Fish, Gianluca Mauri, Nora K. Horick, Jill N. Allen, Lawrence S. Blaszkowsky, Jeffrey W. Clark, David P. Ryan, Ryan D. Nipp, Bruce J. Giantonio, Lipika Goyal, Jon Dubois, Janet E. Murphy, Joseph Franses, Samuel J. Klempner, Eric J. Roeland, Colin D. Weekes, Jennifer Y. Wo, Theodore S. Hong, Emily E. Van SeventerRyan B. Corcoran, Aparna R. Parikh

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

PURPOSE Colorectal cancer (CRC) incidence in patients younger than 50 years of age, commonly defined as early-onset (EO-CRC), is rising. EO-CRC often presents with distinct clinicopathologic features. However, data on prognosis are conflicting and outcomes with modern treatment approaches for metastatic disease are still limited. MATERIALS AND METHODS We prospectively enrolled patients with metastatic CRC (mCRC) to a biobanking and clinical data collection protocol from 2014 to 2018. We grouped the cohort based on age at initial diagnosis: < 40 years, 40-49 years, and ≥ 50 years. We used regression models to examine associations among age at initial diagnosis, treatments, clinicopathologic features, and survival. RESULTS We identified 466 patients with mCRC (45 [10%] age,40 years, 109 [23%] age 40-49 years, and 312 [67%] age ≥ 50 years). Patients < 40 years of age were more likely to have received multiple metastatic resections (odds ratio [OR], 3.533; P = .0066) than their older counterparts. Patients with EO-CRC were more likely to receive triplet therapy than patients.50 years of age (age,40 years: OR, 6.738; P5.0002; age 40-49 years: OR, 2.949; P = .0166). Patients 40-49 years of age were more likely to have received anti-EGFR therapy (OR, 2.633; P = .0016). Despite differences in care patterns, age did not predict overall survival. CONCLUSION Despite patients with EO-CRC receiving more intensive treatments, survival was similar to the older counterpart. However, EO-CRC had clinical and molecular features associated with worse prognoses. Improved biologic understanding is needed to optimize clinical management of EO-CRC. The cost-benefit ratio of exposing patients with EO-CRC to more intensive treatments has to be carefully evaluated.

Original languageEnglish (US)
Pages (from-to)E1846-E1855
JournalJCO Oncology Practice
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Care Patterns and Overall Survival in Patients with Early-Onset Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this